TY - JOUR
T1 - The Landscape of Gut Microbiota and Its Metabolites
T2 - A Key to Understanding the Pathophysiology of Pattern in Chinese Medicine
AU - Zhang, Zhaozhou
AU - Du, Liqing
AU - Ji, Qiuchen
AU - Liu, Hao
AU - Ren, Zhenxing
AU - Ji, Guang
AU - Bian, Zhao Xiang
AU - Zhao, Ling
N1 - This work was supported by the National Natural Science Foundation of China (82204893, 82000504 and 81973538), the Health and Medical Research Fund (17182661), and the Health@ InnoHK Initiative Fund of the Hong Kong Special Administrative Region Government (ITC RC/IHK/4/7).
Publisher Copyright:
© 2024 World Scientific Publishing Company.
PY - 2024
Y1 - 2024
N2 - Liver Stagnation and Spleen Deficiency (LSSD) is a Chinese Medicine (CM) pattern commonly observed in gastrointestinal (GI) diseases, yet its biological nature remains unknown. This limits the global use of CM medications for treating GI diseases. Recent studies emphasize the role of gut microbiota and their metabolites in the pathogenesis and treatment of LSSD-associated GI diseases. There is increasing evidence supporting that an altered gut microbiome in LSSD patients or animals contributes to GI and extra-intestinal symptoms and affects the effectiveness of CM therapies. The gut microbiota is considered to be an essential component of the biological basis of LSSD. This study aims to provide an overview of existing research findings and gaps for the pathophysiological study of LSSD from the gut microbiota perspective in order to understand the relationship between the CM pattern and disease progression and to optimize CM-based diagnosis, prevention, and therapy.
AB - Liver Stagnation and Spleen Deficiency (LSSD) is a Chinese Medicine (CM) pattern commonly observed in gastrointestinal (GI) diseases, yet its biological nature remains unknown. This limits the global use of CM medications for treating GI diseases. Recent studies emphasize the role of gut microbiota and their metabolites in the pathogenesis and treatment of LSSD-associated GI diseases. There is increasing evidence supporting that an altered gut microbiome in LSSD patients or animals contributes to GI and extra-intestinal symptoms and affects the effectiveness of CM therapies. The gut microbiota is considered to be an essential component of the biological basis of LSSD. This study aims to provide an overview of existing research findings and gaps for the pathophysiological study of LSSD from the gut microbiota perspective in order to understand the relationship between the CM pattern and disease progression and to optimize CM-based diagnosis, prevention, and therapy.
KW - Gastrointestinal Diseases
KW - Gut Microbiota
KW - Traditional Chinese Medicine
KW - Pattern Differentiation
KW - Liver Stagnation and Spleen Deficiency
UR - http://www.scopus.com/inward/record.url?scp=85185269261&partnerID=8YFLogxK
U2 - 10.1142/S0192415X24500046
DO - 10.1142/S0192415X24500046
M3 - Journal article
C2 - 38351704
AN - SCOPUS:85185269261
SN - 0192-415X
VL - 52
SP - 89
EP - 122
JO - American Journal of Chinese Medicine
JF - American Journal of Chinese Medicine
IS - 1
ER -